-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Xilio Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2020 to Q3 2025.
- Xilio Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$16.3M, a 16.2% decline year-over-year.
- Xilio Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$58.5M, a 6.87% increase year-over-year.
- Xilio Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$58.2M, a 23.8% increase from 2023.
- Xilio Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$76.4M, a 13.4% increase from 2022.
- Xilio Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$88.2M, a 16.4% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)